HRT Financial’s Grace Therapeutics GRCE Stock Holding History

HRT Financial’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Buy	+62,691	New	+$173K	﹤0.01%	3517
2021 Q1	–	Sell	-936	Closed	-$14K	–	3242
2020 Q4	$14K	Buy	+936	New	+$10.8K	﹤0.01%	1752
2019 Q4	–	Sell	-276	Closed	-$25K	–	1744
2019 Q3	$25K	Buy	+276	New	+$25.6K	﹤0.01%	1330

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial's GRCE Position: Q2 2026 in Review

HRT Financial opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 62,691 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #3517 among its holdings. This is a return to the name: HRT Financial previously reported a position in GRCE as recently as Q4 2020.

HRT Financial first reported a position in GRCE in Q3 2019 and has held it in 3 quarters since. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

HRT Financial held 62,691 shares of Grace Therapeutics worth $142K as of Q2 2026.
Grace Therapeutics was a new HRT Financial position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3517 holding.
HRT Financial first reported a position in Grace Therapeutics in Q3 2019 and has held it in 3 quarters since.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.